Latest news with #diagnostics
Yahoo
13 hours ago
- Business
- Yahoo
Guided Therapeutics Makes Initial Shipment to New Chinese Distribution Partner Hangzhou Dongye Medical Technology, Ltd.
PEACHTREE CORNERS, Ga., July 02, 2025--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced that on June 27th that it made its first shipment of devices and single use components to Hangzhou Dongye Medical Technology Company, Ltd. (HDMT). This order is in addition to future shipments connected with a separate $700,000 purchase order executed earlier this year between HDMT and GTHP. Based on the June 27th shipment, GTHP will recognize an additional $117,462 in sales revenue for the second quarter of 2025. The first three devices from the new $700,000 order have been manufactured and tested, triggering a $70,000 payment from HDMT expected in July 2025. HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive provider of gynecology products for 42 hospitals that perform approximately two million cervical cancer screenings annually. About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings. View source version on Contacts Mark FaupelGuided Therapeutics770-242-8723 Sign in to access your portfolio
Zawya
13 hours ago
- Health
- Zawya
Tapping into the lab economy: Africa's big opportunities in medical research and diagnostics
Africa's fast-growing young population and enthusiastic adoption of digital technology could pave the way for the continent to fast-track science innovation and become a world leader in diagnostics, analysis and research. This is according to industry bodies, speakers and exhibitors of analytica Lab Africa, South Africa's only trade fair for laboratory technology, analysis, biotechnology and diagnostics. Roman Paeske, co-founder and managing director at partnaer, and Dr Aleksandra Nijak-Paeske, PhD – consultant for medical genetics and bioinformatics at partnaer, who will speak at the Lab Forum at analytica Lab Africa, say Africa's diverse populations and potential developments in the regulatory environment offer opportunities for researchers in a number of fields. Paeske says Africa's young, mobile-enabled population has the potential to take the lead in developing mobile-first solutions for healthcare and research. 'It would be very interesting to develop mobile innovations in Africa and position Africa as a leader in this kind of technology,' he says. 'In the medical field, personalised medicine is also a huge trend, so targeted medicine and diagnostics specific for the African population could be fast-tracked here because this population has a different genetic variation than the rest of the world.' Nijak-Paeske says: 'In Europe and the US, researchers are focusing largely on the Caucasian population, whereas diverse population groups in Africa offer huge potential to generate broader databases for genetics, even for stem cell research, which would push forward personalised medicine for various populations.' Medical tourism potential She also sees potential for advanced labs to support medical tourism to Africa. 'Africa has very experienced researchers working on tuberculosis or HIV. This creates opportunities to develop centres for research and treating international patients with HIV or tuberculosis,' she says. 'Another area with growth potential is in vitro fertilisation. IVF regulations in Europe can be challenging, whereas Africa has an opportunity to create an enabling regulatory environment that could support the development of a flourishing international IVF industry and international stem cell research.' Paeske adds that Africa could advance laboratories and overcome many of their challenges by digitising processes, harnessing AI, and making critical resources available locally. 'Africa depends on a lot of imported resources, but the more Africa is able to do it themselves in terms of supplies such as reagents or lab equipment, the more self-sustainable the sector will become. Growing manufacturing and the whole supply chain could create jobs, build skills and grow the industry. I believe the African laboratory sector has huge potential to become a key player from a global perspective.' Value chain opportunities Benjamin Barkley, MD of BennyZA, notes that there are opportunities for suppliers to laboratories to offer more value to support lab progress. He says: 'Scientific institutions, laboratories, and researchers are not typical consumers, and they shouldn't receive typical service. In a field where precision, reliability, and adaptability are critical parameters, off-the-shelf solutions rarely meet the nuanced needs of research environments. "That's why distributors must offer more than just products; they must deliver added value through expert guidance, tailored support, and a deep understanding of the scientific landscape in which they operate. By combining cutting-edge equipment with specialist knowledge and personalised service, distributors can help unlock the full potential of the technology.' On the threshold of rapid progress Alet de Lange, country manager at Esco Technologies South Africa, believes Africa stands at the threshold of a scientific revolution, with laboratories set to play a critical role in advancing healthcare, biotechnology, and pharmaceutical innovation. She says: 'Emerging technologies like mRNA are not only transforming global medicine but also opening new possibilities for localised vaccine production, personalised therapies such as tailored cancer treatments, and disease prevention initiatives for conditions like HIV, malaria, and influenza across the continent.' De Lange notes: 'For Africa to fully harness this potential, investment in state-of-the-art laboratories, equipped with advanced technologies such as isolators, cleanrooms, and biomanufacturing facilities, as well as a strong focus on skilled workforce development, will be essential. Opportunities abound in building local capacity for research and production, reducing reliance on imports, and improving long-term health outcomes. "While challenges such as infrastructure, sustainable funding, and regulatory alignment remain, the outlook is promising. Africa's laboratories are well-positioned to become vibrant centers of innovation that will shape the next generation of healthcare solutions, both regionally and globally.' Addressing key challenges While there are numerous opportunities for the sector, many challenges need to be overcome. Lomo Senoamadi, managing director of Bashumi Instruments and Control Services (BICS), says a key challenge facing laboratory services in Africa is the lack of investment in local capabilities, including infrastructure, technical expertise, and consistent servicing support. 'Many laboratories still rely heavily on imported equipment, consumables, and chemicals. When equipment breaks down or there is a surge in demand, the turnaround time for repairs or replenishments can be lengthy and expensive,' she says. Senoamadi adds: 'There is also a significant gap in training. We need to develop more local technicians who are confident in maintaining and calibrating laboratory equipment. This requires investing in mentorship, practical learning, and upskilling individuals already working in the field." Collaboration is essential for progress, she says: 'Often, individuals and organisations work in isolation, which limits potential advancements. By fostering collaboration across various industries and sectors, we can enhance our collective efforts. Sharing knowledge, creating inclusive opportunities, and supporting one another can significantly strengthen the entire ecosystem. Working together not only drives innovation but also leads to more sustainable outcomes.' Sonja Oosthuizen, regional sales leader at PerkinElmer South Africa, highlights numerous other challenges: 'Some of the key issues our customers face today include limited resources, quality control issues, and workforce shortages. Many laboratories struggle with inadequate funding, which affects their ability to maintain state-of-the-art equipment, hire skilled personnel, and conduct comprehensive research. Ensuring consistent standards is essential for reliable results, but it can be challenging due to varying conditions and the need for rigorous quality management systems. There is also a global shortage of skilled professionals, such as laboratory technicians, scientists, and researchers.' Oosthuizen adds that some of these issues could be reduced by minimising bottlenecks and increasing throughput. 'Efficient workflow optimisation involves careful planning, resource allocation, and technology integration to ensure seamless operations,' she says. Digital technology to drive transformation Steve Sidney, executive director of the National Laboratory Association, South Africa (NLA-SA), says: 'Without a doubt, escalating technological advances and digital transformation have brought with them exciting opportunities for the optimisation of processes and throughput, together with an increase in quality control and compliance.' In the future, improved instrument inter-connectedness due to the internet of things (IoT) will permit more efficient data collection, while automation and robotics for handling equipment, samples and chemicals will impact on productivity and reproducibility, and reduce handling errors, Sidney says. 'Equally, analytics, such as artificial intelligence (AI) and machine learning, will enable the collating and analysing of data from labs across the globe. Visualisation tools such as augmented reality will not only enhance what can be seen with digital information but also enable the real-time capturing of quality control data,' he says. However, he notes that unlocking the potential of these novel technologies comes with increased risks of cyber breaches and cyberattacks, making cyber security of paramount importance to the digital lab. 'In addition, the lab of the future will be under greater pressure in terms of sustainability, energy-efficiency and environmental responsibility, and to design more open co-working areas for better collaboration and teamwork,' Sidney says. 'With today's innovative technologies and tomorrow's emerging and as yet unheard of technologies, it can be safely said that the lab of the future will be an exciting one.' An example of transformative digital technology for the sector is new AI-driven data management and Laboratory Information Management Systems (LIMS). Analytica Lab Africa silver sponsor Lasec® will demonstrate a new LIMS solution at this year's event. Kylie Davis, product portfolio manager at Lasec®. 'Once considered exclusive to specialised labs, LIMS is now more accessible and essential for most laboratories,' she says. Ingrid Woodrow, CEO of analytica Lab Africa industry partner the South African Association for Food Science and Technology (SAAFoST) welcomes the advances shaping the future of testing. 'There are many advanced testing options and fascinating technology used to assist in taking food safety and quality assurance to new heights. I look forward to interacting with all in that space at analytica Lab Africa, and then being able to assist our membership with information and connect with the right companies,' she says. Analytica Lab Africa will be co-located with IFAT Africa at Gallagher Convention Centre in Midrand from 8 to 10 July 2025. Featuring thousands of exhibits and demonstrations including the latest innovations by leading suppliers, practical workshops, and a topical three-day Laboratory Forum programme, analytica Lab Africa offers a unique opportunity for stakeholders from across Africa to discuss the latest industry trends and get hands-on access to the latest laboratory equipment and solutions. The CPD accredited Laboratory Forum will be convened by the Southern African Laboratory Diagnostics Association (SALDA) in collaboration with the African Society for Laboratory Medicine (ASLM) and the Society of Medical Laboratory Technologists of South Africa (SMLTSA), the industry body for South African medical laboratory professionals.
Yahoo
16 hours ago
- Business
- Yahoo
Q1 Earnings Highs And Lows: RadNet (NASDAQ:RDNT) Vs The Rest Of The Testing & Diagnostics Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let's take a look at how RadNet (NASDAQ:RDNT) and the rest of the testing & diagnostics services stocks fared in Q1. The testing and diagnostics services industry plays a crucial role in disease detection, monitoring, and prevention, serving hospitals, clinics, and individual consumers. This sector benefits from stable demand, driven by an aging population, increased prevalence of chronic diseases, and growing awareness of preventive healthcare. Recurring revenue streams come from routine screenings, lab tests, and diagnostic imaging, with reimbursement from Medicare, Medicaid, private insurance, and out-of-pocket payments. However, the industry faces challenges such as pricing pressures, regulatory compliance, and the need for continuous investment in new testing technologies. Looking ahead, industry tailwinds include the expansion of personalized medicine, increased adoption of at-home and rapid diagnostic tests, and advancements in AI-driven diagnostics that enhance accuracy and efficiency. However, headwinds such as reimbursement uncertainties, competition from decentralized testing solutions, and regulatory scrutiny over test validity and cost-effectiveness may impact profitability. Adapting to evolving healthcare models and integrating automation will be key for sustaining growth and maintaining operational efficiency. The 5 testing & diagnostics services stocks we track reported a strong Q1. As a group, revenues beat analysts' consensus estimates by 2.2%. In light of this news, share prices of the companies have held steady as they are up 2.9% on average since the latest earnings results. With over 350 imaging facilities across seven states and a growing artificial intelligence division, RadNet (NASDAQ:RDNT) operates a network of outpatient diagnostic imaging centers across the United States, offering services like MRI, CT scans, PET scans, mammography, and X-rays. RadNet reported revenues of $471.4 million, up 9.2% year on year. This print exceeded analysts' expectations by 6.4%. Overall, it was a strong quarter for the company with a solid beat of analysts' same-store sales estimates. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, 'In February, in conjunction with releasing 2024 fourth quarter results and 2025 guidance ranges, we announced that the first quarter of 2025 was going to be negatively impacted by the Southern California wildfires and the severe winter weather conditions in RadNet's northeast and Houston markets. We report that the impact from these extraordinary events were as previously estimated. Our business significantly recovered in March and has continued to demonstrate strong procedural volumes and Revenue through April and early May.' Interestingly, the stock is up 2.8% since reporting and currently trades at $57.38. Is now the time to buy RadNet? Access our full analysis of the earnings results here, it's free. Pioneering the field of "liquid biopsy" with technology that can identify cancer-specific genetic mutations from a simple blood draw, Guardant Health (NASDAQ:GH) develops blood tests that detect and monitor cancer by analyzing tumor DNA in the bloodstream, helping doctors make treatment decisions without invasive biopsies. Guardant Health reported revenues of $203.5 million, up 20.8% year on year, outperforming analysts' expectations by 6.9%. The business had a stunning quarter with a solid beat of analysts' sales volume estimates and full-year revenue guidance exceeding analysts' expectations. Guardant Health achieved the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise among its peers. The market seems happy with the results as the stock is up 7.5% since reporting. It currently trades at $50.71. Is now the time to buy Guardant Health? Access our full analysis of the earnings results here, it's free. With over 600 million tests performed annually and involvement in 90% of FDA-approved drugs in 2023, Labcorp (NYSE:LH) provides laboratory testing services and drug development solutions to doctors, hospitals, pharmaceutical companies, and patients worldwide. Labcorp reported revenues of $3.35 billion, up 5.3% year on year, falling short of analysts' expectations by 1.9%. It was a softer quarter as it posted a miss of analysts' organic revenue estimates and full-year EPS guidance in line with analysts' estimates. Labcorp delivered the weakest performance against analyst estimates and slowest revenue growth in the group. Interestingly, the stock is up 14.6% since the results and currently trades at $263.69. Read our full analysis of Labcorp's results here. Operating a network of CAP-accredited and CLIA-certified laboratories across the United States and United Kingdom, NeoGenomics (NASDAQ:NEO) provides specialized cancer diagnostic testing services, including genetic analysis, molecular testing, and pathology consultation for oncologists and healthcare providers. NeoGenomics reported revenues of $168 million, up 7.5% year on year. This print came in 1.7% below analysts' expectations. In spite of that, it was a strong quarter as it put up a solid beat of analysts' EPS estimates and full-year revenue guidance beating analysts' expectations. The stock is down 22.8% since reporting and currently trades at $7.70. Read our full, actionable report on NeoGenomics here, it's free. Processing approximately one-third of the adult U.S. population's lab tests annually, Quest Diagnostics (NYSE:DGX) provides laboratory testing and diagnostic information services to patients, physicians, hospitals, and other healthcare providers across the United States. Quest reported revenues of $2.65 billion, up 12.1% year on year. This result beat analysts' expectations by 1.3%. Zooming out, it was a satisfactory quarter as it also recorded an impressive beat of analysts' sales volume estimates but full-year EPS guidance in line with analysts' estimates. Quest had the weakest full-year guidance update among its peers. The stock is up 12.2% since reporting and currently trades at $181.79. Read our full, actionable report on Quest here, it's free. The Fed's interest rate hikes throughout 2022 and 2023 have successfully cooled post-pandemic inflation, bringing it closer to the 2% target. Inflationary pressures have eased without tipping the economy into a recession, suggesting a soft landing. This stability, paired with recent rate cuts (0.5% in September 2024 and 0.25% in November 2024), fueled a strong year for the stock market in 2024. The markets surged further after Donald Trump's presidential victory in November, with major indices reaching record highs in the days following the election. Still, questions remain about the direction of economic policy, as potential tariffs and corporate tax changes add uncertainty for 2025. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
Returns Are Gaining Momentum At Abundance International (Catalist:541)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. So when we looked at Abundance International (Catalist:541) and its trend of ROCE, we really liked what we saw. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Abundance International: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.028 = US$1.2m ÷ (US$75m - US$34m) (Based on the trailing twelve months to December 2024). So, Abundance International has an ROCE of 2.8%. Ultimately, that's a low return and it under-performs the Trade Distributors industry average of 4.2%. See our latest analysis for Abundance International Historical performance is a great place to start when researching a stock so above you can see the gauge for Abundance International's ROCE against it's prior returns. If you're interested in investigating Abundance International's past further, check out this free graph covering Abundance International's past earnings, revenue and cash flow. We're delighted to see that Abundance International is reaping rewards from its investments and is now generating some pre-tax profits. About five years ago the company was generating losses but things have turned around because it's now earning 2.8% on its capital. Not only that, but the company is utilizing 31% more capital than before, but that's to be expected from a company trying to break into profitability. This can tell us that the company has plenty of reinvestment opportunities that are able to generate higher returns. On a side note, Abundance International's current liabilities are still rather high at 45% of total assets. This can bring about some risks because the company is basically operating with a rather large reliance on its suppliers or other sorts of short-term creditors. While it's not necessarily a bad thing, it can be beneficial if this ratio is lower. Long story short, we're delighted to see that Abundance International's reinvestment activities have paid off and the company is now profitable. And since the stock has fallen 44% over the last five years, there might be an opportunity here. With that in mind, we believe the promising trends warrant this stock for further investigation. On a final note, we've found 2 warning signs for Abundance International that we think you should be aware of. While Abundance International may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Returns Are Gaining Momentum At Abundance International (Catalist:541)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. So when we looked at Abundance International (Catalist:541) and its trend of ROCE, we really liked what we saw. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Abundance International: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.028 = US$1.2m ÷ (US$75m - US$34m) (Based on the trailing twelve months to December 2024). So, Abundance International has an ROCE of 2.8%. Ultimately, that's a low return and it under-performs the Trade Distributors industry average of 4.2%. See our latest analysis for Abundance International Historical performance is a great place to start when researching a stock so above you can see the gauge for Abundance International's ROCE against it's prior returns. If you're interested in investigating Abundance International's past further, check out this free graph covering Abundance International's past earnings, revenue and cash flow. We're delighted to see that Abundance International is reaping rewards from its investments and is now generating some pre-tax profits. About five years ago the company was generating losses but things have turned around because it's now earning 2.8% on its capital. Not only that, but the company is utilizing 31% more capital than before, but that's to be expected from a company trying to break into profitability. This can tell us that the company has plenty of reinvestment opportunities that are able to generate higher returns. On a side note, Abundance International's current liabilities are still rather high at 45% of total assets. This can bring about some risks because the company is basically operating with a rather large reliance on its suppliers or other sorts of short-term creditors. While it's not necessarily a bad thing, it can be beneficial if this ratio is lower. Long story short, we're delighted to see that Abundance International's reinvestment activities have paid off and the company is now profitable. And since the stock has fallen 44% over the last five years, there might be an opportunity here. With that in mind, we believe the promising trends warrant this stock for further investigation. On a final note, we've found 2 warning signs for Abundance International that we think you should be aware of. While Abundance International may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
